On June 17, 2020, Zenshine announced its first IND approval from the U.S. Food and Drug Administration (FDA) for 2nd generation PI3Kδ/γ dual inhibitor ZX-101A to enter clinical trial for the treatment of advanced hematological malignancies (ClinicalTrials.gov Identifier: NCT04504708). A phase I/IIa clinical trial is expected to enroll the first patient in the last quarter of 2020. With a focus on unmet medical needs, Zenshine is committed to developing best-in-class and first-in-class small molecule therapeutics to serve under-treated patients. Dr. Jinfu Yang, President of Zenshine, said: "we are very pleased with the IND approval of ZX-101A by the US FDA. This is the first clinical trial approval for Zenshine and an important milestone for our team. We expect to enroll patients late this year and hope that patients can benefit from the treatment with ZX-101A”.